Skip to main content
Livermore
Livermore
ZHEN

D. E. Shaw & Co., Inc.

SEC CIK
0001009207
Latest filing
Aug 14, 2026

TGTX holding history

TG Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

TGTX overviewAll 13F holders of TGTXFull Q2 2026 holdings

Shares (Q2 2026)
3,400,808
Value
$186.8M
% of portfolio
0.1%
Quarters held
22
Since Q1 2021
Holdings of TGTX by D. E. Shaw & Co., Inc., by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20263,400,808$186.8M0.1%+2,810,761+476.4%AddedHolders
Q1 2026590,047$19.6M<0.1%−110,298−15.7%ReducedHolders
Q4 2025700,345$20.9M<0.1%+468,322+201.8%AddedHolders
Q3 2025232,023$8.38M<0.1%+113,886+96.4%AddedHolders
Q2 2025118,137$4.25M<0.1%+56,207+90.8%AddedHolders
Q1 202561,930$2.44M<0.1%−106,573−63.2%ReducedHolders
Q4 2024168,503$5.07M<0.1%−226,276−57.3%ReducedHolders
Q3 2024394,779$9.23M<0.1%+154,767+64.5%AddedHolders
Q2 2024240,012$4.27M<0.1%+150,410+167.9%AddedHolders
Q1 202489,602$1.36M<0.1%−173,176−65.9%ReducedHolders
Q4 2023262,778$4.49M<0.1%+127,581+94.4%AddedHolders
Q3 2023135,197$1.13M<0.1%−1,440,274−91.4%ReducedHolders
Q2 20231,575,471$39.1M0.1%+741,694+89.0%AddedHolders
Q1 2023833,777$12.5M<0.1%−1,370,453−62.2%ReducedHolders
Q4 20222,204,230$26.1M<0.1%+1,503,230+214.4%AddedHolders
Q3 2022701,000$4.15M<0.1%−512,778−42.2%ReducedHolders
Q2 20221,213,778$5.16M<0.1%+943,427+349.0%AddedHolders
Q1 2022270,351$2.57M<0.1%+253,317+1,487.1%AddedHolders
Q4 202117,034$324.0K<0.1%−2,404−12.4%ReducedHolders
Q3 202119,438$647.0K<0.1%−138,142−87.7%ReducedHolders
Q2 2021157,580$6.11M<0.1%−377,421−70.5%ReducedHolders
Q1 2021535,001$25.8M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.